These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 24666019)

  • 1. Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome.
    Cash BD
    Curr Med Res Opin; 2014 Jul; 30(7):1405-15. PubMed ID: 24666019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
    Didari T; Mozaffari S; Nikfar S; Abdollahi M
    World J Gastroenterol; 2015 Mar; 21(10):3072-84. PubMed ID: 25780308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
    Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
    Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.
    Menees SB; Maneerattannaporn M; Kim HM; Chey WD
    Am J Gastroenterol; 2012 Jan; 107(1):28-35; quiz 36. PubMed ID: 22045120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of probiotics in the treatment of irritable bowel syndrome.
    Wilhelm SM; Brubaker CM; Varcak EA; Kale-Pradhan PB
    Pharmacotherapy; 2008 Apr; 28(4):496-505. PubMed ID: 18363533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of irritable bowel syndrome.
    Trinkley KE; Nahata MC
    J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of gut microflora and probiotic effects in the irritable bowel syndrome.
    Fanigliulo L; Comparato G; Aragona G; Cavallaro L; Iori V; Maino M; Cavestro GM; Soliani P; Sianesi M; Franzè A; Di Mario F
    Acta Biomed; 2006 Aug; 77(2):85-9. PubMed ID: 17172187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
    Schey R; Rao SS
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is irritable bowel syndrome an infectious disease?
    Thompson JR
    World J Gastroenterol; 2016 Jan; 22(4):1331-4. PubMed ID: 26819502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?
    Bixquert Jiménez M
    Rev Esp Enferm Dig; 2009 Aug; 101(8):553-64. PubMed ID: 19785495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.